Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

NCT03293498 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: NanoFlu
BIOLOGICAL: Fluzone HD - Day 0
BIOLOGICAL: Fluzone HD - Day 21
OTHER: Saline - Day 21

Sponsor

Novavax